603669 Lionco Pharmaceutical Group
- 4.88
- -0.04-0.81%
Lionco Pharmaceutical Group News
Is Lionco Pharmaceutical GroupLtd (SHSE:603669) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Lingkang Pharmaceutical (603669.SH): Plans to terminate the “Hainan Lingkang Pharmaceutical Mei'an Production Base Construction Project (Phase I)”
Gelonghui, May 16, 丨 Lingkang Pharmaceutical (603669.SH) announced that the fund-raising investment project to be terminated is the “Hainan Lingkang Pharmaceutical Mei'an Production Base Construction Project (Phase I)”, with a total investment of 670,000 yuan and an investment of 525.00 million yuan using raised capital. The implementing entity of this project is Hainan Lingkang Pharmaceutical Co., Ltd., a subsidiary of the company. The implementation site is site B0615, Mei'an Technology New Town Phase 1, Haikou National High-tech Industrial Development Zone, Hainan Province. The amount of capital raised this time was 474.775,800 yuan (including accumulated interest on bank deposits received
There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 26% Price Jump
Despite an already strong run, Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) shares have been powering on, with a gain of 26% in the last thirty days. The bad news is that even after the stock
Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Biggest Owners Are Private Companies Who Got Richer After Stock Soared 18% Last Week
Key Insights Lionco Pharmaceutical GroupLtd's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public The top 2 shareholders own
Lingkang Pharmaceutical (603669.SH) released annual results, with a net loss of 151 million yuan to mother, a year-on-year decrease of 22.65%
According to Zhitong Finance App News, Lingkang Pharmaceutical (603669.SH) released its 2023 annual report. The group achieved operating income of 197 million yuan, a year-on-year decrease of 31.95%; achieved a net loss attributable to shareholders of listed companies of 151 million yuan, a year-on-year narrowing of 22.65%; realized a net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 182 million yuan, a year-on-year decrease of 10.9%; a basic loss per share. The company is mainly engaged in R&D, production and sales of chemical prescription drugs. The company adheres to the market-based product development strategy. The product variety is rich, the structure is reasonable, and numerous
Lingkang Pharmaceutical (603669.SH) announced first-quarter results, with a net loss of 16.0415 million yuan
Lingkang Pharmaceutical (603669.SH) released its report for the first quarter of 2024. The group achieved operating revenue during the period...
Even After Rising 16% This Past Week, Lionco Pharmaceutical GroupLtd (SHSE:603669) Shareholders Are Still Down 44% Over the Past Three Years
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) shareholders will doubtless be very grateful to see the share price up 35% in the last month. But that doesn't change the fact that the returns ov
Revenues Not Telling The Story For Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) After Shares Rise 35%
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) shareholders are no doubt pleased to see that the share price has bounced 35% in the last month, although it is still struggling to make up recently
Some Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Shareholders Look For Exit As Shares Take 31% Pounding
The Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) share price has fared very poorly over the last month, falling by a substantial 31%. Instead of being rewarded, shareholders who have already
Lingkang Pharmaceutical (603669.SH): An estimated loss of 140 million yuan to 169 million yuan in 2023
Gelonghui, January 30丨Lingkang Pharmaceutical (603669.SH) announced its 2023 annual results forecast. According to preliminary estimates by the company's finance department, it is expected to achieve net profit attributable to owners of the parent company in 2023 of -169 million yuan to -140 million yuan. Net profit attributable to the owners of the parent company after deducting non-recurring gains and losses is estimated to be between -21 million yuan and -172 million yuan. It is estimated to achieve operating income of about 20 million yuan in 2023. After deducting business income unrelated to the main business and income without commercial substance, the operating income is 19,
Lingkang Pharmaceutical (603669.SH) obtained a registration certificate for dopamine hydrochloride injection
Lingkang Pharmaceutical (603669.SH) issued an announcement. Recently, the company received the approval and issuance of dopa hydrochloride from the State Drug Administration...
Lingkang Pharmaceutical (603669.SH): A total cost of 48.35 million yuan to buy back 1.1774% of the shares
Gelonghui, January 2, 丨 Lingkang Pharmaceutical (603669.SH) announced that the company first repurchased shares on October 25, 2023. As of December 31, 2023, the company had repurchased 8,491,700 shares through centralized bidding transactions, accounting for 1.1774% of the company's total share capital. The highest transaction price was 6.02 yuan/share, the lowest price was 5.28 yuan/share, and the total amount paid was 48,350,319.00 yuan.
Lingkang Pharmaceutical (603669.SH): Huperzine A for injection is clinically used for benign memory impairment and has an ameliorative effect on patients with dementia and memory impairment caused by organic brain lesions
Gelonghui, December 5, Lingkang Pharmaceutical (603669.SH) stated on an interactive platform that the company's injectable Huperzine A is an exclusive domestic dosage form, which is used to enhance memory, improve memory damage, protect nerves, and increase mental activity. Clinically used for benign memory impairment, it has an effect on improving memory impairment caused by dementia patients and organic brain lesions. It is also used in the treatment of myasthenia gravis.
Lingkang Pharmaceutical (603669.SH): Injectable inflammunine and inflammunine injections held by subsidiaries are suitable for viral pneumonia and viral upper respiratory infections
On December 5, Gelonghui (603669.SH) stated on an interactive platform that the injectable inflammuning and inflammuning injections held by Hainan Lingkang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, are suitable for viral pneumonia and viral upper respiratory infections, and are currently not being produced or sold.
Lingkang Pharmaceutical (603669.SH): A total of 1.1774% of shares have been repurchased at a cost of 48.353 million yuan
Gelonghui on December 4 | Lingkang Pharmaceutical (603669.SH) announced that as of November 30, 2023, the company has repurchased a total of 8.4917 million shares through centralized bidding transactions, accounting for 1.1774% of the company's total share capital. The highest transaction price is 6.02 yuan/share, the lowest price is 5.28 yuan/share, and the total amount paid is 48.353 million yuan (excluding transaction fees).
The cumulative share repurchase ratio of Lingkang Pharmaceutical (603669.SH) reached 1.18% and cost 48.353 million yuan
Lingkang Pharmaceutical (603669.SH) announced that as of November 10, 2023, the company has sold through centralized bidding...
Lingkang Pharmaceutical (603669.SH): Repurchased 0.41% of shares at a total cost of 15.84 million yuan
Gelonghui November 1丨Lingkang Pharmaceutical (603669.SH) announced that the company first repurchased shares on October 25, 2023. As of October 31, 2023, the company had repurchased a total of 2,961,700 shares through centralized bidding transactions, accounting for 0.4106% of the company's total share capital. The highest transaction price was 5.42 yuan/share, the lowest price was 5.28 yuan/share, and the total amount paid was 15,844,652.00 yuan.
Lionco Pharmaceutical GroupLtd (SHSE:603669) Shareholders Are up 13% This Past Week, but Still in the Red Over the Last Three Years
This week we saw the Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) share price climb by 13%. But that doesn't help the fact that the three year return is less impressive. After all, the share
Lingkang Pharmaceutical (603669.SH) repurchased 1,017,000 shares for the first time at a cost of 5.321,900 yuan
Lingkang Pharmaceutical (603669.SH) issued an announcement. On October 25, 2023, the company passed centralized bidding...
[Instant Analysis of BT Financial Report] Lingkang Pharmaceutical 2023 Third Quarter Report: Facing Industry Challenges, Performance Under Pressure
Announcement time of this financial report: 2023-10-20 17:41:20 Lingkang Pharmaceutical Group Co., Ltd. (stock code: 603669) is mainly engaged in R&D, production and sales of chemical prescription drugs. The products cover the three fields of parenteral nutritional drugs, anti-infectives, and digestive system drugs. According to the company's financial report for the third quarter of 2023, we can see that the company's performance is under pressure in the face of industry challenges. First, as can be seen from the balance sheet, the company's total assets were 1,803 billion yuan at the end of this reporting period, down from 1,855 billion yuan at the end of the previous year. At the same time, liabilities
Analysis
Price Target
No Data
